Cohn et al. [16] evaluated four MMR genes, MLH1, MSH2, MSH6, and PMS2, in 336 endometrial cancer samples by immunohistochemistry and found a significantly unfavorable disease-free survival in patients with loss of MLH1 and MSH2 expression compared with normal expression in either protein. This evidence concerns the gene MRC1 and endometrial cancer.